Zimmer BioTech, a skin cancer drug development spinout of Germany-based cryotherapy technology provider Zimmer MedizinSysteme, has raised €7m ($8.2m) in funding.
The capital was supplied by High-Tech Gründerfonds, the German state-managed fund backed by a range of domestic corporates, and Zimmer MedizinSysteme itself.
Founded in October 2016, Zimmer BioTech is developing a drug that will treat the actinic keratosis which can develop into squamous cell carcinoma in fair skin.
The medicine will work in conjunction with photodynamic therapy as an…
